ArticleTechnology in cancer research & treatment
Preparing for the Era of Multiple Primary Cancers: A Prevention-Centered Model for Survivorship Medicine.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of cancer survivors is increasing rapidly, and the development of multiple primary cancers (MPCs) is becoming a foreseeable consequence of long-term survival. However, MPC detection remains fragmented. Clinical information is often scattered across institutions, and long-term follow-up is not always consistent. Early warning signs that appear outside oncology settings are also not always linked to a patient's prior cancer history. As the number of cancer survivors increases, these gaps can have important clinical consequences. This Perspective presents a prevention-centered framework that complements existing survivorship care by recognizing the development of MPCs as an expected event during long-term survivorship. I outline a framework integrating longitudinal genetic and multi-omics risk stratification with artificial intelligence-assisted risk modeling and interoperable health records for continuous monitoring. Extending surveillance beyond oncology clinics to settings such as emergency medicine, primary care, and dentistry, may help detect secondary malignancies earlier. Survivorship medicine should shift from episodic detection to more coordinated, lifelong prevention. Further studies are needed to evaluate this framework across diverse healthcare settings and to determine its potential to improve earlier detection and long-term outcomes for cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.